BriaCell receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Feb 18, 2025

BriaCell Therapeutics Corp.

Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.
Has until Feb 18, 2025 to regain compliance via closing bid price of $1.00+ for 10 consecutive days.
May qualify for second 180-day cure period if it meets other listing standards and effects a reverse split.
TSX listing unaffected; common shares continue trading on Nasdaq under BCTX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.